Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms and Coronary Heart Disease by Dallongeville, Jean et al.
Hindawi Publishing Corporation
PPAR Research
Volume 2009, Article ID 543746, 11 pages
doi:10.1155/2009/543746
Research Article
Peroxisome Proliferator-Activated Receptor Gamma
Polymorphismsand Coronary Heart Disease
JeanDallongeville,1 CarlosIribarren,2 Jean Ferri` eres,3 LiisaLyon,2 AlunEvans,4 AlanS.Go,2
DominiqueArveiler,5 Stephen P. Fortmann,6 PierreDucimeti` ere,7 MarkA. Hlatky,8
Philippe Amouyel,1 Audrey Southwick,9 Thomas Quertermous,10 andAlineMeirhaeghe1
1Service d’Epid´ emiologie et de Sant´ e Publique, Institut Pasteur de Lille, Lille; INSERM, U744, Lille; Universit´ eN o r dd eF r a n c e ,
Lille; UDSL, 59019 Lille, France
2Kaiser Permanente Division of Research, Oakland, CA 94612, USA
3INSERM, U558, Toulouse, Department of Epidemiology, Paul Sabatier-Toulouse Purpan University, 31073 Toulouse, France
4The Department of Epidemiology and Public Health, Queen’s University Belfast, Belfast BT71NN, Northern Ireland, UK
5Department of Epidemiology and Public Health, EA 3430, University of Strasbourg, Faculty of Medicine, 67085 Strasbourg, France
6Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA 94305-5705, USA
7INSERM, U780, 94807 Villejuif, Hˆ opital Kremlin-Bicˆ etre, France
8Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA 94305, USA
9Stanford Human Genome Center, Stanford, CA 94304, USA
10Falk Cardiovascular Research Center, Stanford Falk Cardiovascular Research Building, Stanford, CA 94305-5406, USA
Correspondence should be addressed to Jean Dallongeville, jean.dallongeville@pasteur-lille.fr
Received 11 June 2009; Accepted 26 August 2009
Recommended by Mostafa Badr
Single nucleotide polymorphisms (SNPs) in the peroxisome proliferator-activated receptor γ (PPARG)g e n eh a v eb e e na s s o c i a t e d
with cardiovascular risk factors, particularly obesity and diabetes. We assessed the relationship between 4 PPARG SNPs (C-
681G, C-689T, Pro12Ala, and C1431T) and coronary heart disease (CHD) in the PRIME (249 cases/494 controls, only men)
and ADVANCE (1,076 cases/805 controls, men or women) studies. In PRIME, homozygote individuals for the minor allele of the
PPARG C-689T, Pro12Ala, and C1431T SNPs tended to have a higher risk of CHD than homozygote individuals for the frequent
allele (adjusted OR [95% CI] = 3.43 [0.96–12.27], P = .058, 3.41 [0.95–12.22], P = .060 and 5.10 [0.99–26.37], P = .050, resp.).
No such association could be detected in ADVANCE. Haplotype distributions were similar in cases and control in both studies.
A meta-analysis on the Pro12Ala SNP, based on our data and 11 other published association studies (6,898 CHD cases/11,287
controls), revealed that there was no evidence for a signiﬁcant association under the dominant model (OR = 0.99 [0.92–1.07],
P = .82). However, there was a borderline association under the recessive model (OR = 1.29 [0.99–1.67], P = .06) that became
signiﬁcant when considering men only (OR = 1.73 [1.20–2.48], P = .003). In conclusion, the PPARG Ala12Ala genotype might be
associated with a higher CHD risk in men but further conﬁrmation studies are needed.
Copyright © 2009 Jean Dallongeville et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The peroxisome proliferator-activated receptor γ (PPARG)
is a nuclear hormone receptor that dimerizes with the
retinoid X receptor (RXR) to regulate target genes involved
in adipocyte diﬀerentiation and insulin sensitization [1].
Activation of PPARG with thiazolidinediones is used to
stimulate insulin sensitivity in the treatment of type 2
diabetes. PPARG also plays a role in macrophage, malignant
breast epithelial, colon cancer cell diﬀerentiation, and lipid
homeostasis [2] and has been shown to control the expres-
sion of proinﬂammatory genes in vascular cell models [3].
ThissuggeststhatPPARGmaycontributetothepathogenesis
of the atherosclerotic plaque physiology at a very early stage.
Prior investigations have analyzed the relationship
between common PPARG SNPs and various metabolic
disorders. The Pro12Ala substitution in the speciﬁc exon B
of PPARG2 isoform, which contributes to a lower PPARG22 PPAR Research
activity in vitro, was associated with a decreased risk of type
2 diabetes [4]. Obese carriers of the minor allele of the
PPARG C1431T polymorphism in exon 6 presented higher
plasma leptin levels than noncarriers [5]. The C-681G and
C-689T polymorphisms in the second and third PPARG
promoter, respectively, were both associated with higher
body weight and plasma LDL concentrations [6, 7]. Finally,
haplotype analyses showed that a particular combination
of these 4 polymorphisms was more frequent in patients
with a metabolic syndrome than in control subjects [8].
Altogether, these observations suggest that genetic variability
at the PPARG locus could aﬀect cardiovascular risk.
Early studies analyzed the association between the
PPARG Pro12Ala SNP and coronary heart disease (CHD) in
cohorts from North America. These investigations yielded
inconsistent results [9, 10]. Furthermore, a higher risk
of coronary heart disease was reported in obese subjects
carrying the Ala12 allele that needed conﬁrmation [10].
Therefore, the goal of the present study was to explore the
association between 4 PPARG SNPs, including the Pro12Ala
SNP, and CHD risk in two independent studies among
white subjects. We also performed haplotype analyses to
evaluate whether a particular combination of alleles could
better explain the eﬀect of PPARG genetic variability on
CHDriskandassessedwhetheroverweightandobesitycould
modulate this risk. Finally, we performed a meta-analysis of
published studies to date, focusing on the PPARG Pro12Ala
polymorphism and CHD risk.
2. Methods
2.1. PRIME Study. The PRIME (Prospective Study of
Myocardial Infarction) study is a prospective cohort study
designed to identify risk factors for CHD [11]. Details on
recruitment, baseline examination, and follow-up of the
PRIME Study have been previously reported [12]. Overall,
9758 middle-aged men aged 50–59 years and free of CHD
at baseline were recruited in Lille, Strasbourg, and Toulouse
in France (n = 7399) and Belfast in Northern Ireland (n =




2.1.1. General Characteristics. Subjects who agreed to take
part in the study were given a morning appointment and
askedtofastforatleast12hours.Afulldescriptionofclinical
and laboratory measurements has been published elsewhere
[11, 12]. Brieﬂy, a health questionnaire self-administered
by subjects at their homes was subsequently checked by
trained interviewers at the clinic. It covered a broad range of
clinical information, including family and personal clinical
histories, tobacco consumption, and drug intake. Blood
pressure was measured twice in the sitting position with
the same automatic device (Spengler SP9). A 12-lead ECG
was also recorded. Plasma lipids analyses were centralized
(SERLIA INSERM U325, Institut Pasteur de Lille, France).
Overweight and obesity were deﬁned as BMI ≥ 25kg/m2 and
BMI ≥ 30kg/m2,r e s p e c t i v e l y .
2.1.2. Biochemical Measurements. A subset of biochemical
measurements was performed on the entire cohort at
baseline. Total cholesterol and triglycerides were measured
by enzymatic methods using commercial kits in an auto-
matic analyzer (Boehringer, Mannheim, Germany). High-
density lipoprotein (HDL) cholesterol was determined after
precipitation of Apo-lipoprotein B by an enzymatic method
(Boehringer).Low-densitylipoprotein(LDL)cholesterolwas
calculated according to the Friedewald formula. Insulin
was assayed by competitive radioimmunoassay (Sanoﬁ-
Diagnostic Pasteur, France) in cases and matched controls
using plasma samples collected at baseline and stored in
liquid nitrogen.
During the follow-up, subjects were contacted annually
byletterandaskedtocompleteaclinicaleventquestionnaire.
For all subjects reporting a possible event, clinical informa-
tion was sought directly from the hospital or general prac-
titioner records. All details on ECGs, hospital admissions,
enzymes, surgical intervention, angioplasty, treatments, and
so forth were collected. Death certiﬁcates were checked for
supporting clinical and postmortem information on cause
of death. Whenever possible, circumstances of death were
obtained from the practitioner or the family. A Medical
Committee comprising one member from each PRIME
Center and the Coordinating Center, and three cardiologists
(two from France and one from the UK), was established
to provide an independent validation of coronary events.
A description of the coronary end point deﬁnitions has
been published recently [12]. The ﬁve-year follow-up was
completed in 98,6% of the French participants and 99,2% of
the Northern-Irish participants.
A nested case-control study within the PRIME prospec-
tive cohort study was mounted using the baseline plasma
samples of 335 study participants who subsequently devel-
oped a future coronary ischemic event during follow-up
and of 670 matched controls (2 controls per case). Matched
controls were study participants recruited in the same center,
on the same day (± 3 days), of the same age (± 3 years) as the
case and free of CHD at the time of the ischemic event of the
case. Subjects with incomplete data were excluded. If a case
was excluded, his two matched controls were also excluded,
and if the two matched controls for a case were excluded, the
corresponding case was also excluded. A total of 249 cases
and 494 controls were used in the present study.
2.2. The ADVANCE Study. The Atherosclerotic Disease,
VAscular FuNction, and genetiC Epidemiology (ADVANCE)
study recruited, between October 2001 and December 2003,
a total of 3,179 subjects from multiple race/ethnic back-
ground into 5 cohorts: a cohort of subjects with clinically
signiﬁcant CAD at a young age (≤45 years for males, ≤55
years for females), a cohort of subjects with incident stable
angina at an older age, a cohort of subjects with incident
acute myocardial infarction (AMI) at an older age, a cohort
of young subjects with no history of CAD, and a cohort ofPPAR Research 3
Table 1: Baseline characteristics of subjects with incident CHD (case) and CHD-free (control) subjects in PRIME and ADVANCE.
PRIME Men ADVANCE Men ADVANCE Women
Controls Cases P∗ Controls Cases P∗ Controls Cases P∗
N 494 249 433 706 372 370
Age (y) 55.1 ± 2.8 55.3 ± 3.0 .46 65.8 ± 3.3 61.5 ± 7.9 <.0001 61.5 ± 6.9 60.0 ± 8.8 .11
BMI (kg/m2) 26.7 ± 3.5 27.1 ± 3.4 .11 28.3 ± 4.4 29.1 ± 4.8 .005 27.4 ± 6.3 29.6 ± 7.2 <.0001
Waist girth (cm) 93.6 ± 10.1 95.0 ± 10.2 .067 99.4 ± 12.6 100.0 ± 12.0 .46 83.8 ± 13.6 90.4 ± 15.9 <.0001
Years at school (y) 11.26 ± 5 10.9 ± 3 .36 NA NA NA NA
Physically active (%) 19.6 19.6 .99 62.6 53.8 .004 63.2 45.7 <.0001
Current smokers (%) 30.6 19.7 .0019 6.8 8.4 .36 8.4 13.0 .04
Alcohol consumption (g/week) 236 ± 310 234 ± 323 .88 50 ± 140 20 ± 70 <.0001 20 ± 70 0 ± 30 <.0001
History of hypertension (%) 17.6 30.1 .0001 51.5 78.8 <.0001 41.7 79.2 <.0001
History of dyslipidemia (%) 28.5 34.9 .06 25.4 28.6 .46 11.6 26.2 <.0001
History of diabetes (%) 4.9 8.8 .036 15.5 23.0 <.0001 5.1 21.4 <.0001
Systolic BP (mm Hg) 13 ± 19 141 ± 2 <.0001 131 ± 16 120 ± 17 <.0001 124 ± 19 121 ± 20 .08
Diastolic BP (mm Hg) 84 ± 13 87 ± 12 .0008 75 ± 87 1 ± 9 <.0001 71 ± 96 9 ± 9 .0004
Total cholesterol (mg/dL) 225 ± 37 234 ± 39 .0008 202 ± 35 NA — 210 ± 36 NA —
LDL-cholesterol (mg/dL) 146 ± 34 157 ± 33 .0001 124 ± 30 NA — 124 ± 30 NA —
HDL-cholesterol (mg/dL) 47 ± 12 43 ± 11 <.0001 49 ± 14 NA — 62 ± 17 NA —
Data are expressed as means ± SD or percentages. ∗T-test for continuous variables and Chi-square test for categorical variables. NA: Not available. BP: blood
pressure.
subjects aged 60 to 72 with no history of CAD, ischemic
stroke, or peripheral arterial disease (PAD). Eligible subjects
wereidentiﬁedusingtheKaiserPermanenteofNorthernCal-
ifornia(KPNC)electronicdatabasesandthosewhoagreedto
participate were interviewed and examined at one of several
clinicsintheSanFranciscoBayArea.Asixthcohortofyoung
subjects with no history of CAD included 479 participants
in the Coronary Artery Risk Development in Young Adults
(CARDIA) Study [13] originally recruited through KPNC
and attending the study’s year 15 examination cycle in 2000-
2001. A detailed description of the source population for all
cohorts has been published elsewhere [14, 15]. The design
of the ADVANCE study allowed for several case control
comparisons. In this study, we included all white subjects
with symptomatic early onset CAD (young cases), older
subjects with either AMI or angina as ﬁrst presentation of
CHD (older cases), young controls, and older controls. This
resultedin1076CHDcases(706inmen,370inwomen)and
805 controls (433 male, 372 female).
The ADVANCE study was approved by the Institutional
Review Board at both Stanford University and Kaiser
Permanente of Northern California (KPNC). Details of
the methodology for risk factor assessment can be found
elsewhere [14, 15].
2.3.Genotyping. ThegenotypingmethodinPRIMEhasbeen
described previously [8]. The genotyping success rate was
above 94% for each SNP. Genotyping in ADVANCE was
performed at the Stanford Human Genome Center using the
ABI 7900 TaqMan platform [16, 17]. The “no call rate” for
genotypeswasonly0.35%andthereproducibilitywas99.9%
in random samples with repeat genotypes.
2.4. Statistical Analyses. For ADVANCE, we used uncondi-
tional logistic regression because cases and controls were
not individually matched. For PRIME, we used conditional
logistic regression analysis to compare the distribution of
genotypes between cases and controls and to estimate the
odds ratio (OR) of CHD. The analyses were adjusted for age,
educational level, alcohol consumption, physical activity,
smoking status, history of diabetes, history of hyperten-
sion, and history of dyslipidemia. Additional analyses were
performed to test the interaction between overweight or
obesity and genotype by adding a cross-product term to the
logistic regression model. We used general regression models
and chi-square test to compare the clinical and biological
characteristics of the subjects according to genotype in
controlsubjects.Triglyceridevalueswerelogtransformedfor
analyses. All analyses were performed using SAS software 8.2
version (SAS Institute, Cary, USA).
2.4.1. Haplotype Analyses. Presence of linkage disequilib-
rium between the loci was tested using a log-likelihood-ratio
test [18] and the degree of disequilibrium was expressed in
terms of normalized diﬀerence D  = D/Dmax or D/Dmin
[19]. Haplotype frequencies were estimated using a stochas-
tic version of the expectation-maximization algorithm as
implemented in Thesias software [20, 21]. Diﬀerences in
haplotype frequencies between cases and their respective
controls were examined using a log-likelihood ratio statistic4 PPAR Research
Table 2: PPARG genotype distributions among white CHD cases and CHD-free controls and ORs [95% CI] of CHD.
(a)
PRIME Men
Model 1 Model 2
Controls Cases P∗ OR [95% CI] P OR [95% CI] P
C-681G (n) 484 243
CC, n (%) 286 (59.1) 146 (60.1) reference reference
CG, n (%) 174 (35.9) 79 (32.5) .32 0.88 [0.64–1.22] .44 0.90 [0.64–1.26] .53
GG, n (%) 24 (5.0) 18 (7.4) 1.54 [0.79–3.00] .20 1.64 [0.82–3.30] .16
CG+GG, n (%) 198 (40.9) 97 (39.9) 0.96 [0.71–1.31] .82 0.97 [0.71–1.34] .88
C-689T (n) 484 242
CC, n (%) 374 (77.3) 193 (79.7) reference reference
CT, n (%) 106 (21.9) 42 (17.4) .04 0.76 [0.51–1.13] .18 0.74 [0.49–1.13] .16
TT, n (%) 4 (0.8) 7 (2.9) 3.34 [0.98–11.45] .054 3.43 [0.96–12.27] .058
CT+TT, n (%) 110 (22.7) 49 (20.3) 0.89 [0.61–1.30] .54 0.87 [0.58–1.29] .48
Pro12Ala (n) 486 245
CC, n (%) 378 (77.8) 198 (80.8) reference reference
CG, n (%) 104 (21.4) 40 (16.3) .03 0.74 [0.49–1.10] .14 0.72 [0.47–1.10] .12
GG, n (%) 4 (0.8) 7 (2.9) 3.32 [0.97–11.39] .056 3.41 [0.95–12.22] .060
CG+GG, n (%) 108 (22.2) 47 (19.2) 0.85 [0.58–1.25] .40 0.83 [0.55–1.24] .36
C1431T (n) 482 241
CC, n (%) 383 (79.5) 189 (78.4) reference reference
CT, n (%) 97 (20.1) 46 (19.1) .04 0.94 [0.64–1.38] .76 0.89 [0.60–1.33] .58
TT, n (%) 2 (0.4) 6 (2.5) 5.93 [1.19–29.45] .029 5.10 [0.99–26.37] .050
CT+TT, n (%) 99 (20.5) 52 (21.6) 1.01 [0.69–1.46] .98 0.95 [0.64–1.40] .78
(b)
ADVANCE Men
Model 1 Model 2
Controls Cases P∗ OR [95% CI] P OR [95% CI] P
C-681G (n) 420 694
CC, n (%) 238 (56.7) 395 (56.9) reference reference
CG, n (%) 159 (37.9) 264 (38.1) .95 1.00 [0.78–1.29] .99 1.03 [0.77–1.37] .85
GG, n (%) 23 (5.4) 35 (5.0) 0.92 [0.53–1.59] .76 0.85 [0.46–1.60] .62
CG+GG, n (%) 182 (43.3) 299 (43.1) 0.99 [0.77–1.26] .93 1.00 [0.76–1.32] .99
C-689T (n) 423 687
CC, n (%) 326 (77.1) 522 (76.0) reference reference
CT, n (%) 93 (22.0) 154 (22.4) .68 1.03 [0.77–1.39] .82 1.00 [0.72–1.38] .98
TT, n (%) 4 (0.9) 11 (1.6) 1.72 [0.54–5.44] .35 1.87 [0.48–7.33] .37
CT+TT, n (%) 97 (22.9) 165 (24.0) 1.06 [0.80–1.41] .68 0.99 [0.78–1.26] .94
Pro12Ala (n) 426 693
CC, n (%) 330 (77.5) 528 (76.2) reference reference
CG, n (%) 92 (21.6) 154 (22.2) .62 1.05 [0.78–1.40] .76 1.03 [0.74–1.42] .88
GG, n (%) 4 (0.9) 11 (1.6) 1.72 [0.54–5.44] .36 1.90 [0.49–7.41] .36
CG+GG, n (%) 96 (22.5) 165 (23.8) 1.07 [0.81–1.43] .62 1.06 [0.77–1.45] .74
C1431T (n) 426 687
CC, n (%) 325 (76.3) 530 (77.2) reference reference
CT, n (%) 98 (23.0) 147 (21.4) .50 0.92 [0.69–1.23] .57 0.87 [0.63–1.21] .41
TT, n (%) 3 (0.7) 10 (1.4) 2.01 [0.55–7.36] .29 1.76 [0.43–7.16] .43
CT+TT, n (%) 101 (23.7) 157 (22.8) 0.95 [0.71–1.25] .73 0.90 [0.65–1.24] .52PPAR Research 5
(c)
ADVANCE Women
Model 1 Model 2
Controls Cases P∗ OR [95% CI] P OR [95% CI] P
C-681G (n) 359 365
CC, n (%) 189 (52.7) 203 (55.6) reference reference
CG, n (%) 148 (41.2) 144 (39.5) .64 0.91 [0.67–1.23] .52 0.97 [0.68–1.38] .86
GG, n (%) 22 (6.1) 18 (4.9) 0.76 [0.40–1.47] .42 0.64 [0.30–1.4] .26
CG+GG, n (%) 170 (47.3) 162 (44.4) 0.89 [0.66–1.19] .42 0.92 [0.65–1.29] .62
C-689T (n) 360 365
CC, n (%) 274 (76.1) 285 (78.1) reference reference
CT, n (%) 81 (22.5) 79 (21.6) .26 0.94 [0.66–1.33] .72 1.07 [0.71–1.6] .74
TT, n (%) 5 (1.4) 1 (0.3) 0.19 [0.02–1.66] .13 0.17 [0.02–1.54] .12
CT+TT, n (%) 86 (23.9) 80 (21.9) 0.89 [0.63–1.26] .53 1.00 [0.67–1.49] .99
Pro12Ala (n) 362 366
CC, n (%) 275 (76.0) 288 (78.7) reference reference
CG, n (%) 82 (22.6) 77 (21.0) .22 0.90 [0.63–1.28] .54 1.02 [0.68–1.53] .93
GG, n (%) 5 (1.4) 1 (0.3) 0.19 [0.02–1.65] .13 0.168 [0.02–1.51] .11
CG+GG, n (%) 87 (24.0) 78 (21.3) 0.86 [0.60–1.21] .38 0.99 [0.67–1.49] .80
C1431T (n) 366 367
CC, n (%) 278 (76.0) 281 (76.6) reference reference
CT, n (%) 81 (22.1) 83 (22.6) .50 1.01 [0.72–1.44] .94 1.08 [0.72–1.63] .70
TT, n (%) 7 (1.9) 3 (0.8) 0.42 [0.11–1.66] .21 0.30 [0.07–1.32] .11
CT+TT, n (%) 88 (24.0) 86 (23.4) 0.97 [0.69–1.36] .85 1.00 [0.67–1.49] .96
∗P value for a global test of signiﬁcance. Model 1: crude OR. Model 2: OR adjusted for age, BMI, educational level, smoking status, physical activity, alcohol
intake, history of diabetes, history of hypertension, and history of dyslipidemia.
test which was computed from the estimated haplotype
frequency log-likelihoods for the case and control groups
separately.
2.4.2. Meta-Analysis. In addition to the analysis of PRIME
and ADVANCE, we identiﬁed all published prospective
studies that assessed the relationship between the PPARG
Pro12Ala polymorphism and CHD and conducted a meta-
analysis of the ﬁndings. Inclusion criteria for events were
a coronary event. Inclusion criteria for exposure variable
were the PPARG Pro12Ala polymorphism. Searches were
conductedinelectronicdatabases(MEDLINEandEMBASE)
from 1970 to June 2009. References from the extracted
papers, reviews, and previous meta-analysis were also con-
sulted to complete the data bank. The electronic search
include both truncated free-text and MeSH. Used terms were
“ P P A R G ”o r“ p e r o x i s o m ep r o l i f e r a t o r - a c t i v a t e dr e c e p t o r
gamma” and “polymorphism” and “cardiovascular disease”
or “CAD” or “CHD” or “coronary” or “MI” or “myocardial”
or “ischemic heart disease.” No attempt was made to contact
authors of nonpublished work or to ﬁnd paper in other
languages than English. When the data were not available
in the appropriate format, the corresponding author of the
paper was contacted to obtain the data. However, two studies
were excluded because the data were not available in the
appropriate format, that is, the number of subjects for the
three genotype groups in cases and controls [22, 23]. Finally,
11 studies were selected for the meta-analysis. Therefore,
the ﬁnal data set, including our 3 samples, consisted of
14 independent studies comprising 6898 cases and 11287
controls (Table 4).
For this meta-analysis, we combined data of all studies
using Review Manager software release 5.0 (http://www.cc-
ims.net/revman/)[ 24]. We estimated the overall eﬀect by a
Mantel–Haentzel ﬁxed odds ratio.
3. Results
As expected, major cardiovascular risk factors such as
smoking, history of hypertension, history of dyslipidemia,
history of diabetes, and systolic and diastolic blood pressure
levelsdiﬀeredbetweencasesandcontrolsinbothPRIMEand
ADVANCE studies (Table 1).
The genotype distributions of the 4 PPARG SNPs
respected the Hardy-Weinberg equilibrium in control sub-
jects. In the control group, the frequencies of the PPARG -
681G, -689T, Ala12, and 1431T alleleswere similar in PRIME
and ADVANCE. There were marginal diﬀerences in the
genotype distribution of the C-689T (P = .04), Pro12Ala
(P = .03), and C1431T (P = .04) SNPs between cases6 PPAR Research
Table 3: Estimate of PPARG haplotype frequencies in cases and
controls.
C-681G C-689T Pro12Ala C1431T Controls Cases P
PRIME Men
1 1 1 1 0.72 0.72
2 1 1 1 0.11 0.11
2 2 2 2 0.08 0.09 .53
2 2 2 1 0.04 0.03
1 1 1 2 0.03 0.03
2 1 1 2 0.01 0.02
ADVANCE Men
1 1 1 1 0.74 0.73
2 1 1 1 0.11 0.10
2 2 2 2 0.09 0.08 .38
2 2 2 1 0.03 0.04
1 1 1 2 0.02 0.02
2 1 1 2 0.02 0.01
ADVANCE Women
1 1 1 1 0.71 0.72
2 1 1 1 0.13 0.13
2 2 2 2 0.08 0.08 .70
2 2 2 1 0.04 0.03
1 1 1 2 0.03 0.03
2 1 1 2 0.01 0.01
Only haplotypes with a frequency >1% are displayed. 1 and 2 represent the
frequent andminoralleles, respectively. P va l u ei sf o rt h egl o b a le ﬀect(5df).
and controls in PRIME (Table 2(a)), mainly due to a higher
frequency of homozygote subjects for the minor allele in
cases compared with controls.
The odds ratios (ORs) [95% CI] of CHD were calculated
for heterozygotes, for homozygotes, and for carriers of
the minor allele (dominant model), using both a crude
model and an adjusted model (Table 2(a)). In PRIME,
homozygote individuals for the minor allele of the PPARG
C-689T, Pro12Ala, and C1431T SNPs tended to have a
higher risk of CHD than homozygote individuals for the
frequent allele (OR [95% CI] = 3.34 [0.98–11.45], P =
.054, OR = 3.32 [0.97–11.39], P = .056 and OR = 5.93
[1.19–29.45], P = .029, resp.). After adjustment for age,
educational level, smoking status, physical activity, alcohol
intake, history of diabetes, history of hypertension, and
history of dyslipidemia, the ORs were only slightly altered
(OR = 3.43 [0.96–12.27], P = .058, 3.41 [0.95–12.22],
P = .060 and 5.10 [0.99–26.37], P = .050 for the C-
689T, Pro12Ala and C1431T SNPs, resp.). There was no
signiﬁcant association in ADVANCE, neither in men nor
in women (Table 2(b) and (c)). Further analyses stratifying
on overweight (<25kg/m2 versus ≥25kg/m2)o ro b e s i t y
(<30kg/m2 versus ≥30kg/m2) or adding a cross-product
term into the model yielded no signiﬁcant interaction (all P
values for interaction term >0.1) in both studies (data not
shown).
In control subjects from PRIME and ADVANCE, there
were very few signiﬁcant diﬀerences in baseline charac-
teristics between carriers and noncarriers of the PPARG-
681G, -689T, Ala12, and 1431T alleles (see Tables 1, 2,
3, 4, and 5 in Supplementary Material available online
at doi:10.155/2009/543746). Systolic blood pressure was
signiﬁcantly lower (P<. 05) in carriers of the PPARG-
681G, -689T and Ala12 alleles in PRIME (Supplementary
Table 1). There was no statistically signiﬁcant diﬀerence
in mean BMI, LDL-cholesterol, or HDL-cholesterol levels
between carriers and noncarriers of the minor allele of
any SNP investigated. There was also no evidence for
any statistically signiﬁcant diﬀerence in the prevalence of
reported hypertension, dyslipidemia, or diabetes between
carriers and noncarriers of the minor allele of these SNPs.
The Pro12Ala and the C-681G, C-689T, and C1431T
SNPs were in partial positive linkage disequilibrium
(D  range = +0.6 − +1.0, r2 range = 0.18–0.98). The
C-689T and Pro12Ala SNPs were in perfect linkage dis-
equilibrium (D  = +1.0, r2 = 0.98). The distribution
of the 4 SNP -containing haplotypes was estimated in
cases and controls (Table 3). Six haplotypes covered 98%
of the possible haplotypes. The frequency of the haplotype
composed of the 4 most frequent alleles was >70% in both
casesandcontrols.Therewasnoevidenceforanystatistically
signiﬁcantdiﬀerenceinhaplotypedistributionbetweencases
and controls, neither in PRIME nor in ADVANCE (P>. 38).
Haplotype analyses were also conducted after stratiﬁcation
on overweight or obesity. In these analyses, there was no
evidence of signiﬁcant diﬀerence of haplotype distributions
between cases and controls in overweight or lean, obese, or
nonobese subjects (data not shown).
PooledestimateofCHDoddsratioswerecalculatedfrom
published studies for the PPARG Ala12Pro SNP including
6898 cases and 11287 controls. Funnel plot analysis revealed
no evidence of publication bias. There was no signiﬁcant
association with CHD under the dominant genetic model
(OR = 1.00 [0.93–1.08], P = .95) (Table 4(a)). There was
signiﬁcant heterogeneity in the meta-analysis (Chi2 = 22.10,
df = 13, P = .05) due to the study of Li et al., which was
the only study to show a signiﬁcant association between the
Ala12 allele and a higher CHD risk. When removing this
study from the meta-analysis (heterogeneity Chi2 = 17.37,
df = 12, P = .14), the odds ratio of CHD was 0.99 [0.92–
1.07], P = .82. The ORs of CHD were similar in men (OR =
0.99, P = .91) and women (OR = 0.94, P = .52).
Using the recessive genetic model, there was a borderline
association between the Ala12Ala genotype and CHD risk
(OR = 1.29 [0.99–1.67], P = .06) (Table 4(b)). When
stratifying on gender, Ala12Ala men had a signiﬁcant higher
risk of CHD (OR = 1.73 [1.20–2.48], P = .003) than men
carrying the Pro12 allele (Table 4(c)). No such association
couldbedetectedinwomen(OR =0.62[0.31–1.24],P = .17)
(data not shown).
4. Discussion
In the present study, we did not ﬁnd any consistent
association between the PPARG C-681G, C-689T, Pro12Ala,PPAR Research 7
Table 4
(a) Meta-analysis of CHD risk for the PPARG Pro12Ala polymorphism under the dominant model.
Cases Controls Odds ratio Odds ratio
Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI M-H, Fixed, 95% CI
ADVANCE, Men 165 693 96 426 7.1% 1.07 [0.81, 1.43]
0.50 .71 1 .52
ADVANCE, Women 78 366 87 362 5.4% 0.86 [0.60, 1.21]
Bluher et al., Men + Women 27 201 24 164 1.8% 0.91 [0.50, 1.64]
Li et al., Men + Women 23 218 38 626 1.4% 1.83 [1.06, 3.14]
Pischon et al., Men 63 250 95 502 3.7% 1.44 [1.00, 2.07]
Pischon et al., Women 58 245 99 485 4.0% 1.21 [0.84, 1.75]
PRIME, Men 47 245 108 486 4.6% 0.83 [0.57, 1.22]
Ridker et al., Men 98 523 482 2092 12.3% 0.77 [0.60, 0.98]
Ruiz et al., Men + Women 365 1805 335 1805 20.9% 1.11 [0.94, 1.31]
Tobin et al., Men + Women 113 547 124 505 8.0% 0.80 [0.60, 1.07]
Vogel et al., Men 197 786 216 880 12.0% 1.03 [0.82, 1.28]
Vogel et al., Women 64 245 208 789 5.7% 0.99 [0.71, 1.37]
Vos et al., Men 126 563 134 646 7.6% 1.10 [0.84, 1.45]
Zafarmand et al., Women 44 211 376 1519 5.7% 0.80 [0.56, 1.14]
Total (95% CI) 6898 11287 100.0% 1.00 [0.93, 1.08]
Total events 1468 2422
Heterogeneity: Chi
2 = 22.10, df = 13 (P = .05); I2 = 41%
Test for overall eﬀect: Z = 0.06 (P = .95)
(b) Meta-analysis of CHD risk for the PPARG Pro12Ala polymorphism under the recessive model.
Cases Controls Odds ratio Odds ratio
Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI M-H, Fixed, 95% CI
ADVANCE, Men 11 693 4 426 4.9% 1.70 [0.54, 5.38]
0.02 0.1 1 10 50
ADVANCE, Women 1 366 5 362 5.0% 0.20 [0.02, 1.68]
Bluher et al., Men + Women 4 201 2 164 2.2% 1.64 [0.30, 9.09]
Li et al., Men + Women 0 218 2 626 1.3% 0.57 [0.03, 11.95]
Pischon et al., Men 4 250 4 502 2.6% 2.02 [0.50, 8.16]
Pischon et al., Women 4 245 6 485 4.0% 1.33 [0.37, 4.74]
PRIME, Men 7 245 4 486 2.6% 3.54 [1.03, 12.23]
Ridker et al., Men 6 523 31 2092 12.3% 0.77 [0.32, 1.86]
Ruiz et al., Men + Women 24 1805 25 1805 24.8% 0.96 [0.55, 1.69]
Tobin et al., Men + Women 10 547 4 505 4.1% 2.33 [0.73, 7.48]
Vogel et al., Men 21 786 12 880 11.1% 1.99 [0.97, 4.06]
Vogel et al., Women 2 245 15 789 7.1% 0.42 [0.10, 1.87]
Vos et al., Men 21 563 12 646 10.8% 2.05 [1.00, 4.20]
Zafarmand et al., Women 3 211 30 1519 7.2% 0.72 [0.22, 2.37]
Total (95% CI) 6898 11287 100.0% 1.29 [0.99, 1.67]
Total events 118 156
Heterogeneity: Chi
2 = 15.93, df = 13 (P = .25); I2 = 18%
Test for overall eﬀect: Z = 1.90 (P = .06)8 PPAR Research
(c) Meta-analysis of CHD risk for the PPARG Pro12Ala polymorphism under the recessive model in men.
Cases Controls Odds ratio Odds ratio
Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI M-H, Fixed, 95% CI
ADVANCE, Men 11 693 4 426 11.0% 1.70 [0.54, 5.38]
0.10 .20 .51 2 5 1 0
Pischon et al., Men 4 250 4 502 5.9% 2.02 [0.50, 8.16]
PRIME, Men 7 245 4 486 5.9% 3.54 [1.03, 12.23]
Ridker et al., Men 6 523 31 2092 27.8% 0.77 [0.32, 1.86]
Vogel et al., Men 21 786 12 880 25.0% 1.99 [0.97, 4.06]
Vos et al., Men 21 563 12 646 24.4% 2.05 [1.00, 4.20]
Total (95% CI) 3060 5032 100.0% 1.73 [1.20, 2.48]
Total events 70 67
Heterogeneity: Chi
2 = 4.93, df = 5( P = .42); I2 = 0%
Test for overall eﬀect: Z = 2.96 (P = .003)
orC1431TSNPsorrelatedhaplotypesandCHDrisk,neither
in men nor in women, in the PRIME and ADVANCE
studies. Furthermore, analyses stratiﬁed on overweight or
obesity revealed no evidence that these PPARG variants
inﬂuence CHD risk in overweight or obese men. These
data do not support the hypothesis that PPARG C-681G,
C-689T, Pro12Ala, and C1431T polymorphisms are major
risk factors for CHD but does not rule out the possibility of
an association of small magnitude, especially in homozygote
Ala12Ala men.
PPARG is a ligand-activated transcription factor playing
an important role in adipocyte diﬀerentiation, glucose
homeostasis, and several vascular processes. In vitro studies
have shown that the PPARG Ala12 allele decreases PPARG
activation of reporter genes (4) and the -681G and -689T
alleles are associated with lower PPARG promoter activity
[4, 6, 7] suggesting that carriers of these alleles might have
a lower PPARG-mediated activation of target genes than
noncarriers.
Earlier clinical and epidemiological studies have assessed
the relationship between variability at the PPARG gene loci
and CHD risk. The results of these investigations have been
inconsistent with some studies showing a reduced risk of
coronary heart disease [9, 22], other studies an increased
risk [25–29] and some others reporting no association [10,
23, 30–33]. In contrast, three studies showed less intima-
media carotid thickening in carriers of the PPARG Ala12
allele suggesting a possible relation between this variant and
sub-clinical atherosclerosis [34–36].
We found no consistent association for none of the 4
PPARG SNPs (C-681G, C-689T, Pro12Ala, and C1431T)
in PRIME and ADVANCE. Only in PRIME, we observed
that men homozygotes for the minor allele of the C-689T,
Pro12Ala, and C1431T SNPs had a higher risk of CHD than
homozygotes for the frequent allele. This result was further
conﬁrmed in the meta-analysis including 3060 cases and
5032 controls that showed a higher risk of CHD in Ala12Ala
men. Recent genome whole association studies failed to
identify associations with PPARG SNPs [37–42]. Firstly, this
might be explained by the gender-speciﬁc eﬀect and the
restrictive recessive genetic model of the PPARG association.
Secondly, the 4 SNPs that were investigated in the present
study may not be the culprit ones, but rather be in linkage
disequilibriumwithacausalmutation,resultinginadilution
of a possible association.
PPARG SNPs may aﬀect CHD risk through their asso-
ciation with cardiovascular risk factors. In the present
study, we found no evidence for signiﬁcant diﬀerences in
major cardiovascular risk factors for example, body mass
index, lipid levels, or history of diabetes, between carriers
and noncarriers of the minor alleles. The only exception
was a borderline association with systolic blood pressure
level which was lower in PPARG-681G, -689T, and Ala12
carriers than in noncarriers in the PRIME study and could
confer some protection against CHD. These ﬁndings are in
agreement with other studies which showed lower levels of
blood pressure or risk of hypertension in carriers of the
minor allele of the PPARG Pro12Ala SNP [43–45]. However,
these associations are inconsistent across studies as some
also reported higher levels [46, 47] or not signiﬁcantly
diﬀerent levels [48, 49] of blood pressure between carriers
and noncarriers of the PPARG Ala12 allele. In this sample of
apparently healthy men, the prevalence of hypertension was
low (∼18%) and the impact of the PPARG-681G, -689T, and
Ala12 alleles on blood pressure was clinically limited.
An earlier study has reported a signiﬁcant higher risk of
MI and fatal CHD in overweight but not in normal weight
subjects [10] suggesting that the impact of PPARG genotype
may diﬀer according to body fat mass. In the present study,
which has a similar number of cases and controls, we found
no evidence for such a relationship, suggesting that obesity is
not a determinant of the association between PPARG genetic
variability and CHD.
5. Conclusion
In the present study, there was no major consistent associ-
ation between the PPARG C-681G, C-689T, Pro12Ala, and
C1431T genotypes or related haplotypes and CHD risk.
When combining our data with previous cohort studies,
focusingonthePPARGPro12AlaSNP,wefoundasigniﬁcant
association between the homozygote Ala12Ala genotype and
a higher risk of CHD in men. Further studies are needed to
deﬁnitely conclude.PPAR Research 9
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